MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated Retained Earnings 2011-2026 | CORT
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 544 M | 403 M | 296 M | 195 M | 82.5 M | -23.6 M | -118 M | -193 M | -322 M | -330 M | -324 M | -293 M | -247 M | -209 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 544 M | -330 M | -38.5 M |
Quarterly Retained Earnings Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 619 M | 599 M | 564 M | 513 M | 466 M | 430 M | 371 M | 340 M | 312 M | - | 280 M | - | 218 M | 195 M | 163 M | 132 M | 106 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -23.6 M | -23.6 M | -23.6 M | -23.6 M | -118 M | -118 M | -118 M | -118 M | -193 M | -193 M | -193 M | -193 M | -322 M | -322 M | -322 M | -322 M | -330 M | -330 M | -330 M | -330 M | -324 M | -324 M | -324 M | -324 M | -293 M | -293 M | -293 M | -293 M | -247 M | -247 M | -247 M | -247 M | -209 M | -199 M | -192 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 619 M | -330 M | -43.7 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-1.3 B | $ 18.38 | -0.68 % | $ 2.7 B | USA |
 |
Amgen
AMGN
|
-27.6 B | $ 344.65 | 0.81 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 B | $ 71.99 | 3.84 % | $ 9.63 B | USA |
 |
Biogen
BIIB
|
19.3 B | $ 178.18 | -0.95 % | $ 25.9 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.65 | 1.92 % | $ 16.6 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
-311 M | $ 2.96 | 7.64 % | $ 167 M | China |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 4.16 | 3.74 % | $ 9.05 B |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.18 | 0.32 % | $ 7.65 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Compugen Ltd.
CGEN
|
-489 M | $ 1.86 | 1.1 % | $ 167 M | Israel |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 24.86 | 1.06 % | $ 1.6 M | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 3.87 | 2.22 % | $ 116 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.61 B | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 224.87 | -0.54 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 110.01 | -3.29 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-406 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.39 | 1.5 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
-384 M | $ 1.73 | -1.43 % | $ 82.4 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
-286 M | $ 21.75 | 0.65 % | $ 2.11 B | France |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-607 M | $ 14.25 | 4.13 % | $ 4.4 B | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-1.77 B | $ 6.72 | 2.05 % | $ 1.39 B | USA |